Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Pantoprazole in Cisplatin Nephrotoxicity

Phase 3

Recruiting

Conditions: Oncology

Interventions: Other: Standard hydration
Drug: Pantoprazole high dose
Drug: Pantoprazole low dose
Drug: Cisplatin

First Posted Date: 2020-01-03

Last Posted Date: 2020-01-03

Lead Sponsor: Sherief Abd-Elsalam

Target Recruit Count: 60

Registration Number: NCT04217512

Locations: 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2

Active, not recruiting

Conditions: Bladder Urothelial Carcinoma
Stage III Bladder Cancer AJCC v8

Interventions: Procedure: Biopsy of Bladder
Procedure: Biospecimen Collection
Drug: Cisplatin
Procedure: Computed Tomography
Procedure: Cystoscopy
Biological: Durvalumab
Other: Patient Observation
Drug: Gemcitabine Hydrochloride
Drug: Fluorouracil
Procedure: Magnetic Resonance Imaging
Drug: Mitomycin
Radiation: Radiation Therapy

First Posted Date: 2020-01-02

Last Posted Date: 2025-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT04216290

Locations: 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
Logan Health Medical Center, Kalispell, Montana, United States
🇺🇸
Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States

and more 214 locations

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

Early Phase 1

Active, not recruiting

Conditions: Malignant Pelvic Neoplasm
Recurrent Gastric Carcinoma
Recurrent Liposarcoma
Recurrent Ovarian Carcinoma
Recurrent Rhabdomyosarcoma
Refractory Colon Carcinoma
Malignant Abdominal Neoplasm
Refractory Ovarian Carcinoma
Recurrent Colon Carcinoma
Recurrent Desmoplastic Small Round Cell Tumor

Interventions: Drug: Cisplatin
Procedure: Cytoreductive Surgery
Drug: Doxorubicin
Drug: Hyperthermic Intraperitoneal Chemotherapy
Drug: Sodium Thiosulfate
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Procedure: Biospecimen Collection

First Posted Date: 2019-12-30

Last Posted Date: 2024-08-26

Lead Sponsor: Mayo Clinic

Target Recruit Count: 2

Registration Number: NCT04213794

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Phase 3

Active, not recruiting

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)
Gastroesophageal Junction Carcinoma (GEJC)
Esophageal Adenocarcinoma (EAC)

Interventions: Biological: pembrolizumab
Drug: placebo
Drug: cisplatin
Drug: 5-FU
Radiation: radiotherapy
Drug: leucovorin
Drug: levoleucovorin
Drug: oxaliplatin

First Posted Date: 2019-12-24

Last Posted Date: 2024-11-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 703

Registration Number: NCT04210115

Locations: 🇺🇸
Greater Baltimore Medical Center ( Site 0031), Baltimore, Maryland, United States
🇺🇸
Allegheny Health Network ( Site 0042), Pittsburgh, Pennsylvania, United States
🇧🇷
ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0088), Ijui, Rio Grande Do Sul, Brazil

and more 167 locations

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Metastatic Squamous Non-Small Cell Lung Cancer
Metastatic Nonsquamous Non-Small Cell Lung Cancer

Interventions: Drug: Retifanlimab
Drug: Placebo
Drug: Pemetrexed
Drug: Cisplatin
Drug: Paclitaxel
Drug: Carboplatin
Drug: nab-Paclitaxel

First Posted Date: 2019-12-19

Last Posted Date: 2024-10-16

Lead Sponsor: Incyte Corporation

Target Recruit Count: 583

Registration Number: NCT04205812

Locations: 🇹🇷
Trakya Universitesi Tip Fakultesi, Edirne, Turkey
🇿🇦
Wits Clinical Research, Johannesburg, South Africa
🇺🇦
Kherson Regional Oncologic Dispensary, Kherson, Ukraine

and more 135 locations

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Phase 1

Completed

Conditions: Biliary Tract Cancer

Interventions: Drug: CPI 613
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2019-12-18

Last Posted Date: 2024-07-11

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 75

Registration Number: NCT04203160

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
University Hospitals - Seidman Cancer Center, Cleveland, Ohio, United States
🇺🇸
Northwestern University -- Lurie Comprehensive Cancer Center, Chicago, Illinois, United States

and more 7 locations

INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)

Phase 3

Withdrawn

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Retifanlimab
Drug: Placebo
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Drug: Etoposide
Radiation: Radiotherapy

First Posted Date: 2019-12-18

Last Posted Date: 2020-06-09

Lead Sponsor: Incyte Corporation

Registration Number: NCT04203511

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Selpercatinib
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed
Drug: Pembrolizumab

First Posted Date: 2019-12-11

Last Posted Date: 2024-06-20

Lead Sponsor: Loxo Oncology, Inc.

Target Recruit Count: 261

Registration Number: NCT04194944

Locations: 🇨🇳
The First Affiated Hospital Of Guangzhou Medical Collage, Guangzhou, Guangzhou, China
🇦🇷
Alexander Fleming, Ciudad de Buenos Aires, Argentina
🇨🇳
Buddhist Dalin Tzu Chi General Hospital, Dalin Town, Chiayi, Taiwan

and more 191 locations

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

Phase 2

Conditions: Small Cell Lung Cancer Limited Stage

Interventions: Drug: Sintilimab
Drug: Etoposide
Drug: Cisplatin
Radiation: radiotherapy

First Posted Date: 2019-12-06

Last Posted Date: 2019-12-06

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 140

Registration Number: NCT04189094

Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery

Phase 1

Recruiting

Conditions: Stage IIIB Vulvar Cancer AJCC v8
Stage II Vulvar Cancer AJCC v8
Stage IIIA Vulvar Cancer AJCC v8
Stage IIIC Vulvar Cancer AJCC v8
Stage III Vulvar Cancer AJCC v8
Stage IVA Vulvar Cancer AJCC v8

Interventions: Drug: Cisplatin
Radiation: External Beam Radiation Therapy
Drug: Nelfinavir

First Posted Date: 2019-11-20

Last Posted Date: 2024-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT04169763

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy